Product Information

Sunitinib Malate

Item No. 13159

Sold for research purposes under agreement from Pfizer Inc.

CAS Registry No.: 341031-54-7
Formal Name: N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide,(2S)-hydroxy-Butanedioic acid
Synonyms: Sutent™, SU 11248
MF: $C_{22}H_{27}FN_4O_2 \cdot C_4H_6O_5$
FW: 532.6
Purity: ≥98%
Stability: ≥2 years at -20°C
Supplied as: A crystalline solid



Laboratory Procedures

For long term storage, we suggest that sunitinib malate be stored as supplied at -20°C. It should be stable for at least two years.

Sunitinib malate is supplied as a crystalline solid. A stock solution may be made by dissolving the sunitinib malate in an organic solvent purged with an inert gas. Sunitinib malate is soluble in organic solvents such as DMSO and dimethyl formamide. The solubility of sunitinib malate in DMSO is approximately 5 mg/ml and approximately 1 mg/ml in DMF.

Sunitinib malate is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, sunitinib malate should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. Sunitinib malate has a solubility of approximately 0.25 mg/ml in a 1:3 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Sunitinib malate is a small molecule, multi-targeted receptor tyrosine kinase inhibitor. It potently inhibits signaling through PDGFR, VEGFR, KIT, and FLT3.[1] Through these effects, sunitinib malate inhibits both tumor cell growth and angiogenesis, leading to reduced tumor vascularization and cancer cell death.[2,3] It has been approved by the FDA for the treatment of gastrointestinal stromal tumors and metastatic renal cell carcinoma.

References

1. O'Farrell, A.-M., Abrams, T.J., Yuen, H.A., *et al.* SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity *in vitro* and *in vivo*. *Blood* **101**, 3597-3605 (2003).
2. Mendel, D.B., Laird, A.D., Xin, X., *et al. In vivo* antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationship. *Clin. Cancer Res.* **9**, 327-337 (2003).
3. Motzer, R.J., Michaelson, M.D., Redman, B.G., *et al.* Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. *J. Clin. Oncol.* **24(1)**, 16-24 (2006).

Related Products

For a list of related products please visit: www.caymanchem.com/catalog/13159

Cayman Chemical

Mailing address
1180 E. Ellsworth Road
Ann Arbor, MI
48108 USA

Phone
(800) 364-9897
(734) 971-3335

Fax
(734) 971-3640

E-Mail
custserv@caymanchem.com

Web
www.caymanchem.com